DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
53	シェーグレン症候群	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02495129 (ClinicalTrials.gov)	December 2015	8/7/2015	Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome	A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjögren's Syndrome Using [Zr-89]-Rituximab PET/CT	Primary Sjögren's Syndrome	Drug: VAY736 lower dose;Drug: VAY736 higher dose	Novartis Pharmaceuticals	NULL	Withdrawn	N/A	N/A	All	0	Phase 1;Phase 2	Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02495129
(ClinicalTrials.gov)

December 2015

8/7/2015

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjögren's Syndrome Using [Zr-89]-Rituximab PET/CT

Primary Sjögren's Syndrome

Drug: VAY736 lower dose;Drug: VAY736 higher dose

Novartis Pharmaceuticals

NULL

Withdrawn

N/A

All

Phase 1;Phase 2

Netherlands